Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
Houvenaeghel G, Cohen M, Raro P, De Troyer J, de Lara CT, Gimbergues P, Gauthier T, Faure-Virelizier C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo PE, Lambaudie E, Tallet A, Boher JM; Others investigators (SERC trial group). Houvenaeghel G, et al. Among authors: jouve e. BMC Cancer. 2018 Nov 21;18(1):1153. doi: 10.1186/s12885-018-5053-7. BMC Cancer. 2018. PMID: 30463611 Free PMC article. Clinical Trial.
Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A, Gonçalves A, Zemmour C, Cohen M, Classe JM, Reyal F, Colombo PE, Jouve E, Giard S, Barranger E, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G. de Nonneville A, et al. Among authors: jouve e. Eur J Cancer. 2017 Oct;84:34-43. doi: 10.1016/j.ejca.2017.06.043. Epub 2017 Aug 4. Eur J Cancer. 2017. PMID: 28780480
Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study.
Martinez A, Filleron T, Rouanet P, Méeus P, Lambaudie E, Classe JM, Foucher F, Narducci F, Gouy S, Guyon F, Marchal F, Jouve E, Colombo PE, Mourregot A, Rivoire M, Chopin N, Houvenaeghel G, Jaffre I, Leveque J, Lavoue V, Leblanc E, Morice P, Stoeckle E, Verheaghe JL, Querleu D, Ferron G. Martinez A, et al. Among authors: jouve e. Ann Surg Oncol. 2018 Feb;25(2):535-541. doi: 10.1245/s10434-017-6120-z. Epub 2017 Nov 20. Ann Surg Oncol. 2018. PMID: 29159738
Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.
de Nonneville A, Jauffret C, Gonçalves A, Classe JM, Cohen M, Reyal F, Mazouni C, Chauvet MP, Chopin N, Colombo PE, Jouve E, Darai E, Rouzier R, Coutant C, Gimbergues P, Azuar AS, de Lara CT, Lambaudie E, Houvenaeghel G. de Nonneville A, et al. Among authors: jouve e. Breast Cancer Res Treat. 2019 Jun;175(2):379-387. doi: 10.1007/s10549-019-05160-9. Epub 2019 Feb 13. Breast Cancer Res Treat. 2019. PMID: 30759288 Clinical Trial.
Tubular and mucinous breast cancer: results of a cohort of 917 patients.
Roux P, Knight S, Cohen M, Classe JM, Mazouni C, Chauvet MP, Reyal F, Colombo PE, Jouve E, Chopin N, Daraï E, Coutant C, Lambaudie E, Houvenaeghel G. Roux P, et al. Among authors: jouve e. Tumori. 2019 Feb;105(1):55-62. doi: 10.1177/0300891618811282. Epub 2018 Dec 20. Tumori. 2019. PMID: 30900967
Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions.
Uzan C, Mazouni C, Rossoni C, De Korvin B, de Lara CT, Cohen M, Chabbert N, Zilberman S, Boussion V, Vincent Salomon A, Espie M, Coutant C, Marchal F, Salviat F, Boulanger L, Doutriaux-Dumoulin I, Jouve E, Mathelin C, de Saint Hilaire P, Mollard J, Balleyguier C, Joyon N, Triki ML, Delaloge S, Michiels S. Uzan C, et al. Among authors: jouve e. Ann Surg Oncol. 2021 Apr;28(4):2138-2145. doi: 10.1245/s10434-020-09107-z. Epub 2020 Sep 12. Ann Surg Oncol. 2021. PMID: 32920723 Free article.
External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis.
Houvenaeghel G, El Hajj H, Barrou J, Cohen M, Raro P, De Troyer J, Gimbergues P, Tunon de Lara C, Ceccato V, Vaini-Cowen V, Faure-Virelizier C, Marchal F, Gauthier T, Jouve E, Theret P, Regis C, Desmons F, Tallet A, Boher JM; The Serc Trial Group. Houvenaeghel G, et al. Among authors: jouve e. Cancers (Basel). 2020 Oct 11;12(10):2924. doi: 10.3390/cancers12102924. Cancers (Basel). 2020. PMID: 33050650 Free PMC article.
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial.
Houvenaeghel G, Cohen M, Raro P, De Troyer J, Gimbergues P, Tunon de Lara C, Ceccato V, Vaini-Cowen V, Faure-Virelizier C, Marchal F, Gauthier T, Jouve E, Theret P, Regis C, Gabelle P, Pernaut J, Del Piano F, D'Halluin G, Lantheaume S, Darai E, Beedassy B, Dhainaut-Speyer C, Martin X, Girard S, Villet R, Monrigal E, Hoyek T, Le Brun JF, Colombo PE, Tallet A, Boher JM; SERC trial group. Houvenaeghel G, et al. Among authors: jouve e. NPJ Breast Cancer. 2021 Oct 8;7(1):133. doi: 10.1038/s41523-021-00336-3. NPJ Breast Cancer. 2021. PMID: 34625562 Free PMC article.
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.
Houvenaeghel G, de Nonneville A, Chopin N, Classe JM, Mazouni C, Chauvet MP, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher JM. Houvenaeghel G, et al. Among authors: jouve e. Cancer Med. 2023 Feb;12(4):4023-4032. doi: 10.1002/cam4.5257. Epub 2022 Sep 20. Cancer Med. 2023. PMID: 36127853 Free PMC article.
166 results